Abstract
Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.
| Original language | English (US) |
|---|---|
| Title of host publication | Gastrointestinal Cancers |
| Subtitle of host publication | Prevention, Detection and Treatment |
| Publisher | Nova Science Publishers, Inc. |
| Pages | 1-40 |
| Number of pages | 40 |
| Volume | 2 |
| ISBN (Electronic) | 9781536101799 |
| ISBN (Print) | 9781536101690 |
| State | Published - Jan 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Colorectal polyps and carcinoma : Role of the pathologist. / Kashikar, Nilesh; Garcia-Buitrago, Monica.
Gastrointestinal Cancers: Prevention, Detection and Treatment. Vol. 2 Nova Science Publishers, Inc., 2016. p. 1-40.Research output: Chapter in Book/Report/Conference proceeding › Chapter
}
TY - CHAP
T1 - Colorectal polyps and carcinoma
T2 - Role of the pathologist
AU - Kashikar, Nilesh
AU - Garcia-Buitrago, Monica
PY - 2016/1/1
Y1 - 2016/1/1
N2 - Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.
AB - Colorectal carcinoma is the third most common cancer in the United States in both men and women, and subsequently it is also the third leading cause of cancer-related death in the United States. In the era of personalized medicine, gastroenterologists, colorectal surgeons, oncologists and medical geneticists have started depending on the pathologist’s consultation in the management of patients with colorectal polyps or carcinoma. The pathologist’s role is not restricted to mere histomorphologic subtyping but is greatly expanding to provide accurate pathologic stage, analysis of surgical resection margins, identification of prognostic parameters that are not included in the staging such as lymph-vascular and perineural invasion, tumor budding, and assessment of therapeutic effect in patients who have received neoadjuvant therapy. With the rapid therapeutic advancement in available therapeutic options, pathologists also play a leading role in assessing mismatch repair protein expression, selecting appropriate tissue sections for microsatellite instability testing and KRAS, NRAS, BRAF, and PIK3CA mutation analysis, and in interpreting the results of these important therapeutic and prognostic tests. This chapter focuses in the role of the pathologist evaluating preneoplastic lesions, malignant polyps and familial polyposis as well as colorectal carcinoma and its predictor and prognostic factors.
UR - http://www.scopus.com/inward/record.url?scp=85029915098&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85029915098&partnerID=8YFLogxK
M3 - Chapter
SN - 9781536101690
VL - 2
SP - 1
EP - 40
BT - Gastrointestinal Cancers
PB - Nova Science Publishers, Inc.
ER -